文献速递浆细胞疾病

评估单药KappaMab及KappaMab联合来那度胺和低剂量地塞米松治疗复发和/或难治性κ轻链限制型多发性骨髓瘤的序贯队列研究(AMaRC 01-16)

A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16).
PubMed 文献 · Br J Haematol · 2023-06-26

该IIb期序贯队列研究在复发/难治性κ轻链限制型多发性骨髓瘤患者中给予单药KappaMab(KM)或KM联合来那度胺和地塞米松(KM-Rd),KM-Rd总缓解率为82.5%,优于澳大利亚和新西兰骨髓瘤及相关疾病登记处(MRDR)接受Rd的真实世界匹配病例对照队列的45.1%。单药KM和KM-Rd耐受性良好,KM-Rd安全性与其他临床背景下仅接受Rd的患者相似。基于优异的安全性和显著疗效,计划开展进一步临床试验以增加KM剂量并将KM与其他标准治疗联合。

要点

  • KM-Rd总缓解率82.5%,优于MRDR中接受Rd的真实世界队列的45.1%。
  • 单药KM和KM-Rd均耐受性良好,KM-Rd安全性与其他背景下仅用Rd者相似。
  • 基于安全性和疗效,计划开展KM剂量递增及与其它标准治疗联用的进一步临床试验。

核心结论

  • KM-Rd在复发/难治性κ轻链限制型多发性骨髓瘤中显示出优于真实世界Rd队列的缓解率,且安全性良好。
  • 基于优异的安全性和显著疗效,计划开展进一步临床试验以增加KM剂量并将KM与其他标准治疗联合。

研究设计与样本

  • IIb期序贯队列研究,在复发、难治性κ轻链限制型多发性骨髓瘤患者中给予单药KM或KM联合来那度胺和地塞米松(KM-Rd)。
  • 另纳入澳大利亚和新西兰骨髓瘤及相关疾病登记处(MRDR)接受Rd的真实世界匹配病例对照队列,与KM-Rd队列进行比较。

主要发现

  • KM-Rd的总缓解率为82.5%,MRDR中接受Rd的真实世界队列为45.1%。
  • 单药KM和KM-Rd方案均耐受性良好,KM-Rd的安全性与其他临床背景下仅接受Rd的患者相似。

关键数值与推荐

  • KM-Rd总缓解率82.5%,MRDR接受Rd的真实世界队列总缓解率45.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KappaMab (KM; formerly MDX-1097) is a monoclonal antibody specific for the kappa myeloma antigen (KMA), a cell-surface antigen expressed on malignant plasma cells in kappa-restricted multiple myeloma (κMM), some lymphomas, occasional tonsillar B cells and in vitro activated B cells, but not on normal B cells in bone marrow. Phase I/IIa studies of single-agent KM confirmed a favourable toxicity profile and evidence of anti-myeloma activity. Ex-vivo studies demonstrating upregulation of KMA by lenalidomide, and enhanced effector-cell cytotoxicity provided the rationale for this phase IIb study where KM or KM in combination with lenalidomide and dexamethasone (KM-Rd) was administered in relapsed, refractory κMM patients. In addition, outcomes for a real-world matched case-control cohort from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) who received Rd were compared to the KM-Rd cohort. KM-Rd demonstrated an overall response rate of 82.5% which compared favourably to the Rd-MRDR cohort of 45.1%. Both single-agent KM and KM-Rd regimens were well tolerated, with the KM-Rd safety profile similar to patients given only Rd in other clinical settings. Based on the excellent safety profile and significant efficacy, further clinical trials escalating the KM dose and pairing KM with other standard-of-care treatments are planned.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Spencer A, Kalff A, Shortt J, et al. A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16). Br J Haematol. 2023. PMID: 37357593. doi:10.1111/bjh.18955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。